Data mining analysis of mir-638 and key genes interaction in cisplatin resistant triple-negative breast cancer

Cisplatin is one of the chemotherapy for the treatment of triple-negative breast cancer (TNBC), but its effectiveness is limited because of the phenomenon of chemoresistance. miR-638 was shown to regulate chemoresistance; however, it has never been validated in the cisplatin-resistant tumor from patients. This present study aimed to identify the key gene regulatory networks of miR-638 and evaluate the potential role of the miR-638 and its targets as potential prognosis biomarkers for cisplatin-resistance triple-negative breast cancer patients. The miR-638 target was obtained from the miRecords database while the mRNA of chemoresistance biomarker candidate was obtained from the GSE18864 of GEO database, which is mRNA of cisplatin-resistance TNBC patients. CCND1 and FZD7 are potential candidates for cisplatin chemoresistance biomarkers in patients with TNBC. Moreover, a Kaplan-Meier survival plot showed that breast cancer patients with low mRNA levels of FZD7 had significantly worse overall survival than those in higher mRNA expression group. Taken together, miR-638 plays a role in cisplatin resistance mechanism through a mechanism involving its target gene CCND1 and FZD7. Overall, miR-638, CCND1, and FZD7 are candidates for cisplatin biomarker resistance in TNBC.